XenoSTART Company Profile

Background

Overview

XenoSTART is an oncology translational research organization specializing in the development and utilization of patient-derived xenograft (PDX) models. Established in 2007, XenoSTART operates as a preclinical research division within The START Center for Cancer Research, an international cancer treatment and research organization. This collaboration enables XenoSTART to generate clinically relevant PDX models that closely mirror real-world patient disease complexity.

Mission and Vision

XenoSTART's mission is to advance oncology drug development by providing high-quality, patient-derived models that bridge the gap between preclinical research and clinical application. The organization envisions accelerating the development of novel anti-cancer therapies through its comprehensive PDX model platform.

Primary Area of Focus

XenoSTART focuses on creating and characterizing PDX models derived from patient tumor tissues. These models are extensively annotated with clinical histories, genomic profiles, histologic analyses, and in vivo drug sensitivity data, facilitating the evaluation of drug efficacy and resistance mechanisms.

Industry Significance

As a leader in the field of oncology translational research, XenoSTART plays a crucial role in bridging the gap between laboratory research and clinical application. Its PDX models are instrumental in accelerating drug discovery and development, thereby contributing to the advancement of personalized cancer therapies.

Key Strategic Focus

Core Objectives

• Accelerate Drug Development: Utilize PDX models to expedite the evaluation of oncology therapeutics, reducing the time from discovery to clinical application.

• Enhance Model Relevance: Ensure that PDX models accurately represent the heterogeneity and complexity of human tumors to improve the predictive value of preclinical studies.

• Support Personalized Medicine: Provide models that aid in understanding individual patient responses to treatments, facilitating the development of personalized cancer therapies.

Specific Areas of Specialization

• Comprehensive PDX Model Repository: Maintain an extensive collection of over 2,800 PDX models across 27 tumor types, each characterized by detailed clinical annotations and molecular profiling.

• In Vivo Efficacy Studies: Conduct preclinical studies to assess the pharmacokinetics, pharmacodynamics, and efficacy of oncology drugs using PDX models.

• Custom Model Development: Offer tailored PDX models to meet specific research needs, including orthotopic and radiotherapy studies, ex vivo and organoid studies, and cell line development.

Key Technologies Utilized

• Genomic Profiling: Employ next-generation sequencing to analyze genetic alterations in PDX models, providing insights into tumor biology and potential therapeutic targets.

• Histologic Analysis: Utilize advanced histological techniques to examine tissue architecture and cellular composition within PDX models.

• In Vivo Drug Sensitivity Testing: Assess the response of PDX models to various oncology drugs in vivo, aiding in the identification of effective treatments.

Primary Markets or Conditions Targeted

• Oncology Drug Developers: Provide preclinical models to pharmaceutical and biotechnology companies for drug discovery and development.

• Academic and Research Institutions: Support cancer research by offering models that reflect human tumor biology.

• Clinical Trial Organizations: Assist in designing and optimizing clinical trials by providing models that predict patient responses to treatments.

Financials and Funding

Funding History

Specific details regarding XenoSTART's funding history, including total funds raised and recent funding rounds, are not publicly disclosed. As a privately held entity, such information is typically confidential.

Notable Investors

Information about individual investors or venture capital firms backing XenoSTART is not publicly available.

Intended Utilization of Capital

While specific utilization plans are not disclosed, capital raised by XenoSTART is likely directed towards:

• Expanding PDX Model Repository: Increasing the diversity and number of models to cover a broader range of tumor types and patient demographics.

• Enhancing Research Capabilities: Investing in advanced technologies and methodologies to improve model characterization and drug testing accuracy.

• Operational Scaling: Strengthening infrastructure and personnel to support growing demand from research and pharmaceutical partners.

Pipeline Development

Key Pipeline Candidates

XenoSTART's pipeline primarily consists of its extensive collection of PDX models, which serve as tools for evaluating various oncology therapeutics. These models are not standalone drug candidates but are integral to the preclinical assessment of drug efficacy and resistance.

Stages of Clinical Trials or Product Development

XenoSTART's PDX models are utilized in the preclinical stage of drug development. They are employed to:

• Assess Drug Efficacy: Determine the effectiveness of new oncology drugs before clinical trials.

• Understand Mechanisms of Resistance: Identify how tumors may resist treatments, informing the development of combination therapies.

• Guide Clinical Trial Design: Provide data that assist in designing clinical trials with a higher likelihood of success.

Target Conditions

The PDX models cover a wide array of cancer types, including but not limited to:

• Lung Cancer

• Prostate Cancer

• Breast Cancer

• Colorectal Cancer

• Leukemias

Each model is characterized to reflect the heterogeneity and complexity of human tumors, aiding in the development of personalized cancer therapies.